FINWIRES · TerminalLIVE
FINWIRES

Coda Minerals Raises Nearly AU$7 Million via Share Placement; Shares Down 10%

By

Coda Minerals (ASX:COD) raised AU$6.7 million through an oversubscribed placement of 51.5 million shares at AU$0.13 apiece, according to a Monday filing with the Australian bourse.

The placement also includes an attaching option in the existing listed CODO class exercisable at AU$0.15 each, expiring on March 28, 2029, based on one option for every four shares subscribed, the filing said.

Proceeds will be used to advance key pre-feasibility study workstreams at the company's Elizabeth Creek project in South Australia, per the filing.

Shares fell 10% in recent trade on Monday.

Related Articles

Asia

DroneShield Falls After Shareholders Deliver First Strike Against Remuneration Report

DroneShield (ASX:DRO) shares fell nearly 12% in recent Monday trade after it said late Friday that shareholders delivered a first strike against the company's remuneration report at its annual general meeting.Around half of shareholders voted against a resolution to adopt the remuneration report at the May 29 meeting.Under Australia's Corporations Act, a first strike occurs when a listed company's remuneration report receives a "no" vote from at least 25% of shareholders. A second strike has the potential to lead to a re-election of the board.In February, DroneShield adopted new trading and disclosure policies to address the findings of a governance review, which was conducted in response to an ASX letter in November 2025. The letter detailed concerns regarding the company's practices around market disclosure and trading by directors and senior executives.

$ASX:DRO
Asia

Shionogi & Co Secures US FDA Approval for Oral Antiviral to Prevent COVID-19 After Exposure

The US Food and Drug Administration approved Shionogi & Co's (TYO:4507) Xocova or ensitrelvir as the first and only oral antiviral for post-exposure prophylaxis of COVID-19 in individuals aged 12 and older, according to a Tokyo bourse filing on Monday.The approval, which came ahead of the June 16 Prescription Drug User Fee Act action date, was supported by Phase 3 Scorpio-PEP trial results, which showed a 67% reduction in symptomatic COVID-19 risk following exposure compared to placebo.The treatment was generally well tolerated, with adverse event rates similar to placebo, and no reports of altered taste attributed to the drug.

$TYO:4507
Asia

PlaySide Studios Sees AU$4 Million Revenue Hit in Fiscal Year 2027 After Meta Contract Termination, Shares Hit Nearly One-Year Low

PlaySide Studios (ASX:PLY) was informed by Meta Platforms Technologies that Meta will terminate the company's outsourced development contracts on the Horizon Worlds social platform, with all work expected to conclude by July 31, according to a Monday Australian bourse filing.The company said management anticipates the revenue impact from the loss of the work will be about AU$4 million in fiscal 2027, while fiscal year 2026 revenue guidance remains unchanged, and the cash balance at June 30 is expected to be about AU$14 million to AU$15 million.There is no change to the company's development progress on the upcoming title Game of Thrones: War for Westeros, the post-launch roadmap for MOUSE: P.I For Hire or its Dew publishing agreement, the filing added.The company started a consultancy process with several employees that will likely result in redundancies, with the goal of realigning its cost base, and will provide a further update on the outcome in due course.The company's shares fell 21% in recent trade and earlier reached their lowest since July 2025.

$ASX:PLY